Combination Molecularly Targeted Drug Therapy in Metastatic Melanoma: Progress to Date

Drugs ◽  
2013 ◽  
Vol 73 (8) ◽  
pp. 767-777 ◽  
Author(s):  
Charlotte Lemech ◽  
Jeffrey Infante ◽  
Hendrik-Tobias Arkenau
2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e14004-e14004
Author(s):  
Takumi Ochiai ◽  
Kazuhiko Nishimura ◽  
Tomoo Watanabe ◽  
Masayuki Kitajima ◽  
Akinori Nakatani ◽  
...  

e14004 Background: An increase in serum iron levels after administration of various anticancer drugs was reported (Follezou et al, NEOPLASMA 1985). We have also reported an increase in serum iron levels during FOLFOX and FOLFIRI therapies (ASCO 2009: #e15110) and a correlation between prognosis and transition of serum iron levels in advanced colorectal cancer (CRC) patients (ASCO 2011: #e14141). The aim of this cohort study was to evaluate the correlation between prognosis and serum iron levels in advanced CRC patients treated with FOLFOX/FOLFIRI ± molecularly targeted drugs. Methods: Serum iron levels were measured before and at 48 hr after treatment (FOLFOX/FOLFIRI ± molecularly targeted drugs) in 69 advanced CRC patients, all of whom died between December 2005 and December 2011. No patients were treated with radiotherapy. Taking the median rate of increase in serum iron levels as the cut-off value in each therapy, the patients were categorized into cohort I (increase rate over cut-off value in at least one therapy) and cohort II (increase rate under the cut-off value in all therapies). Prognosis was evaluated between the two cohorts using the Kaplan-Meier method and the log rank test. Results: No significant bias in patient characteristics was observed between the two cohorts. Serum iron levels transiently increased after treatment (p<0.001), then returning to baseline within 2 weeks. Median survival time (MST) in cohort I (n: 41) and cohort II (n: 28) was 430 and 377 days, respectively. The MST was significantly better in cohort I (p=0.0496). No significant differences were observed in the frequency of chemotherapies or number of patients treated with molecularly targeted drugs between the two cohorts. Conclusions: Cohort I showed a statistically significant better prognosis. The results suggest that serum iron levels could be used as a new predictive factor in FOLFOX/FOLFIRI ± molecularly targeted drug therapy. In Cohort II patients, molecularly targeted drugs should be used positively for further improvement in prognosis.


2021 ◽  
Author(s):  
Na Li ◽  
Shangcong Han ◽  
Baohua Ma ◽  
Xia Huang ◽  
Lisa Xu ◽  
...  

With increasing understanding of the role of autophagy in tumorigenesis and development, studies have demonstrated that both excessive induction and inhibition of autophagy could improve the efficacy against tumors during cytotoxic or molecularly targeted drug therapy.


2016 ◽  
Vol 4 (1) ◽  
pp. 7 ◽  
Author(s):  
Jyotibala Banjare

Obesity is a medical condition arises as a result of an imbalance between lipolysis and lipogenesis which leads to accumulation of excess fat. Obesity is linked with major health complications such as diabetes, cardiac disorder, cancer, hypertension, sleep apnoea, etc. Weight loss through medication and healthy food balance can prevent obesity and associated disorders. Though, diet based therapy and drugs have short term effect with lacunae. At present, no reliable and established oral supplements are available to take care of obesity. Nanotechnology is a briskly emerging area of science and technology for food modulation at molecular and atomic level. The unique size and superior properties of nanomaterial have huge application in biology and medicine for food and drug development. Nanotechnology is playing an important role in the food industry for unindustrialized improved food, uptake, absorption, and bioavailability of nutrients to the body. Balanced or better-modified nutrients food, restricted calorie measures and commercial availability is geared through Nanoscience for control of obesity. Nanoparticle Targeted drug therapy, particularly for adipose tissue, may provide a new generation formulation for therapeutics of obesity.


2018 ◽  
Vol 53 ◽  
pp. 22-36 ◽  
Author(s):  
Habibollah Faraji ◽  
Reza Nedaeinia ◽  
Esmaeil Nourmohammadi ◽  
Bizan Malaekeh-Nikouei ◽  
Hamid Reza Sadeghnia ◽  
...  

Nanotechnology as a multidisciplinary and scientific innovation plays an important role in numerous biomedical applications, such as molecular imaging, biomarkers and biosensors and also drug delivery. A wide range of studies have been conducted on using of nanoparticles for early diagnosis and targeted drug therapy of various diseases. In fact, the small size, customized surface, upgraded solubility, or multi-functionality of nanoparticles enabled them to interact with complex cellular functions in new ways which opened many doors and created new biomedical applications. These studies demonstrated that nanotechnology vehicles can formulate biological products effectively, and this nano-formulated products with a potent ability against different diseases, were represented to have better biocompatibility, bioaccessibility and efficacy, under in vitro and in vivo conditions.


Peptides 1992 ◽  
1993 ◽  
pp. 819-820
Author(s):  
L. A. Vilaseca ◽  
K. Rose ◽  
R. Werlen ◽  
A. Meunier ◽  
R. E. Offord ◽  
...  
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document